|Jun 26, 2014||Auxilium Pharmaceuticals to Merge with Canadian Biotechnology Company QLT|
|Accelerates Auxilium's Ongoing Transformation Into Leading North American Specialty Biopharmaceutical Company
Canadian-Domiciled Structure Creates Stronger Financial Position, Competitive Partnering and M&A Platform
Platform Enables Continued Product and Therapeutic Diversification; Expands Geographic Footprint
CHESTERBROOK, Pa. and VANCOUVER, Canada, June 26, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company... |
|Jun 25, 2014||Sobi files for EU approval of Xiapex for Peyronies disease|
|STOCKHOLM and CHESTERBROOK, Pa., June 25, 2014 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi) and Auxilium Pharmaceuticals, Inc. today announced that Sobi has filed for an extension of the label for Xiapex® (collagenase clostridium histolyticum) with the European Medicines Agency (EMA) to include the indication of Peyronie's disease.
The filing is based on positive safety and efficacy outcome data from two double-blind placebo-controlled studies, IMPRESS I and II (The Investigation... |
|Jun 11, 2014||Auxilium Pharmaceuticals, Inc. Announces Launch Of Authorized Generic Version Of Testim (Testosterone Gel)|
|CHESTERBROOK, Pa., June 11, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that it has partnered with Prasco, LLC ("Prasco") to introduce an Authorized Generic version of Testim® (testosterone gel). Prasco has product inventory available and has commenced shipping product. Testim and its Authorized Generic version are testosterone gels approved by the U.S. Food and Drug Administration to treat adult male... |
|Jun 2, 2014||Auxilium Pharmaceuticals, Inc. Announces Departure of Chief Financial Officer|
|CHESTERBROOK, Pa., June 2, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that James E. Fickenscher, Chief Financial Officer, is leaving the Company to pursue other interests. Mr. Fickenscher will continue in his current role through August 15, 2014.
"The Board and I want to thank Jim for his nine years of service and important contributions to the evolution of Auxilium," said Adrian Adams, Chief Exe... |